in mesangial cells (MC), and that this action is signalled by receptor mediated activation of protein kinase C (PKC). In the present study, we examined the hypothesis that activation of PKC by TX signals increases in transforming growth factor /3 (TGF-/3) bioactivity, which in turn induces enhanced matrix protein synthesis. In cultured rat MC, the TXAJ prostaglandin endoperoxide analogue U-46619, but not exogenous human platelet TGF-/31, activated PKC as reflected by enhanced in situ phosphorylation of MARCKS protein, an endogenous substrate of PKC. U-46619 and TGF-/31 stimulated fibronectin (Fn) synthesis in MC, as shown by [35S]methionine incorporation into immunoprecipitable Fn. Pan-specific rabbit anti-TGF-f3 antibody blocked the increases in Fn synthesis induced by exogenous TGF-/3 and those induced by U-46619 at 24 to 72 hours after addition. Anti-TGF-/3 antibody did not block the small increases in Fn synthesis observed six hours after addition of U-46619, suggesting that this acute response was not dependent on TGF-/3. Anti-TGF-13 antibody also failed to block activation of PKC by U-46619. U-46619 and 50 n of the PKC agonist phorbol dibutyrate (PDBu) significantly increased both the active fraction and total (latent plus active) TGF-/3 in MC culture media, as assayed with the mink lung epithelial cell bioassay system. PKC inhibition with bisindolylmaleimide GF 109203X (GFX) or down-regulation of PKC in MC by prior exposure to a high concentration (0.5 j.tM) of phorbol myristate acetate (PMA) blocked increases in TGF-/3 bioactivity induced by either U-46619 or PDBu. PKC down-regulation in MC also blocked increases in Fn synthesis induced by U-46619. By contrast, exogenous TGF-/3 stimulated Fn synthesis in both intact MC and in MC with down-regulated PKC. The findings indicate that activation of PKC by U-46619 signals an increase in TGF-j3 bioactivity, which in turn stimulates Fn synthesis in MC by processes not dependent on PKC.
Thromboxane (TX) has been implicated in the pathogenesis of renal injury in experimental models of nephropathy, as well as in some human renal disorders [1-71. Thus, TX synthetase inhibitors ameloriate pathological changes in the kidneys of patients with cyclosporine toxicity [3] , and prevent increases in basement membrane protein mRNA levels in the kidneys of diabetic mice [7] . TX antagonists improve renal function in lupus nephritis [4] , and in post-obstructive nephropathy [5] , as well as preventing albuminuria and increases in glomerular matrix expansion in the streptozotocin diabetic rat [6] . Many earlier studies focused on the actions of TX as a platelet aggregator and vasoconstrictor in the mediation of renal dysfunction [8] . However, direct effects of TX on the mesangial cell (MC) have now been demonstrated that may contribute to the development of glomerulosclerosis. Bruggeman et al found that TX increases human MC synthesis of type IV collagen, laminin, and fibronectin and the mRNA levels of these proteins [9, 10] . Mene et al similarly showed that TX stimulates protein synthesis, including collagen type IV, in cultured human MC [11] . Fibronectin (Fn) accumulation is also increased in rat MC exposed to TX and a high ambient concentration of glucose [12] . The pathways through which TX induces changes in MC matrix protein synthesis are incompletely understood. MC have high affinity TX receptors [13, 14] . Upon binding to these receptors, TX activates phospholipase C, stimulates increases in inositol phosphate turnover, elevates cytosolic calcium and diacylglycerol, and activates protein kinase C [14] [15] [16] [17] . Recent studies in our laboratory [17] have implicated rapid activation of protein kinase C (PKC) by TX as a signal for increased Fn synthesis in MC. However, the pathway by which activation of PKC subsequently initiates an increase in Fn synthesis in MC is not known.
Transforming growth factor J3 (TGF-/3) is a potent stimulus of MC matrix protein synthesis and also inhibits degradation of these proteins [18, 19] . There is now strong evidence to support a pathogenetic role for TGF-j3 in glomerulosclerosis [20] [21] [22] [23] [24] [25] [26] , including the demonstration in vivo that renal transfection with cDNA for TGF-/31 leads to the development of this histologic change [27] . In preliminary studies, we found evidence of a role for TGF-f3 in the expression of the action of TX to increase Fn synthesis in MC after 24 hours [28] . Thus, anti-TGF-f3 antibody blocked TX induced increases in Fn synthesis in MC, and TX increased TGF-13 bioactivity in MC culture media [28] . TGF-f3 has similarly been implicated in the mediation of several other agents to increase MC matrix protein synthesis, including high ambient concentrations of glucose [29] , low density lipoproteins [30] and angiotensin II [31] . Notably, all of these stimuli of matrix protein synthesis activate PKC [30, 32, 33] . In the present study, we examined the possibility that TX activation of PKC is a signal to increase TGF-/3 bioactivity in MC, which in turn mediates the sustained increases in Fn synthesis observed in response to TX. calf serum (FCS), 100 U/mi penicillin, 100 g/ml streptomycin, 5 g/ml insulin, 5 jg/m1 transferrin, and 5 nglml sodium selenite (Sigma Chemical Co., St. Louis, MO, USA) at 37°C in 5% CO2 and 95% air. At confluence, MC were routinely rendered quiescent by incubation in media with FCS reduced to 1% for 24 hours. Test agents were then added. Cell passages 2 to 8 were used in these studies.
Bioassay of TGF-J3 activity TGF-13 bioactivity in MC culture media was assayed using the mink lung epithelial cell (MLEC) assay with minor modifications of published procedures [34, 35] , as previously reported from this laboratory [30] . Briefly, media were collected from MC cultured as described in the figure legends. Bovine serum albumin (BSA) and protease inhibitors were added to final concentrations of 1 mg/ml BSA and 1 g/ml each of aprotinin, leupeptin, and pepstatin. The samples were centrifuged to remove cell debris and held at 4°C until assayed. Latent TGF-13 was activated by heating media to 80°C for 15 minutes. MLEC, American Type Culture CCL-64, were seeded in MEM supplemented with 10% FCS, antibiotics, and glutamine. After six hours, medium FCS was reduced to 0.5% and the culture continued for 18 hours. Media from MC cultures or an equivalent volume of unconditioned MC media (RPMI-1640) containing exogenous TGF-131 standards were added to the MLEC. After 24 hours, the cells were pulse [35S]-Met labeled Fn was immunoprecipitated with human Fn antiserum (Collaborative Research Inc., Bedford, MA, USA) and assayed as previously described [12] . Fn synthesis is expressed as dpm/103 cells or dpm/.tg protein, determined using bicinchoninic acid (Sigma Chemical Co.).
PKC activity
In situ PKC activity was determined as previously reported in detail from this laboratory [12, 17] . Briefly, MC were grown to confluence, media serum reduced to 1%, and the cells labeled with 32P-orthophosphate (New England Nuclear, Boston, MA, USA) for four hours. MC were exposed to test agents as described in the figure legends and the acid soluble 80 kD myristoylated alanine rich C kinase substrate (MARCKS) protein extracted and separated by electrophoresis. The PKC data are expressed as density units, calculated as the ratio of the phosphorylation of the 80 kD MARCKS protein to a 40 kD reference protein, whose phosphorylation did not change under the conditions studied.
Materials
Materials were obtained from sources noted above, or as previously reported [30] .
Statistics
Experiments were performed at least three times and data shown as means SE. Each incubation condition was represented by duplicate or triplicate wells. Replicates from a single culture were averaged and entered as one value for purposes of statistical analysis. ANOVA was performed to compare multiple groups, and the significance of differences between mean values was determined by Student's t-test.
Results
Fn synthesis in MC exposed to 1 jM of the TXA2/prostaglandin endoperoxide analog U-46619 for 24 hours was approximately 2.5-fold higher than control (Fig. 1) . As previously reported [17] , this concentration of U-46619 induced maximal increases in Fn synthesis at 24 hours. As is also shown in Figure 1 anti-TGF-/3 antibody had no effect on this response (Fig. 1) . In contrast to U-46619, however, concentrations of exogenous TGF-3 from 1 p ( Values are means se (N = 4). *P < 0.05 versus corresponding control.
less than 2% of control values [12, 17, 36] . As shown in of TGF-J3 in media by 145% over basal (0.53 M to 1.3 pM), and increased total (latent + active) TGF-/3 bioactivity by 43% (32 to 46 pM). Figure 3 also shows the effects on these TGF-13 bioactivities of bisindolylmaleimide GF 109203X (GFX), a potent and relatively specific inhibitor of PKC [361. We have previously shown that GFX blocks the Fn synthetic response to U-46619 in MC [17] . GFX did not alter basal accumulation of total TGF-f3 bioactivity in media, but suppressed the basal level of the active fraction to 30% of the value observed in cultures exposed to the GFX vehicle alone. By contrast, GFX completely blocked the increases in both active and total TGF-f3 bioactivity induced by U-46619.
The role of PKC in the expression of the action of U-46619 to increase TGF-13 bioactivity in MC cultures was further examined in MC whose PKC was down-regulated by exposure to PMA for 24 hours prior to the addition of U-46619 (Fig. 4) . U-46619 failed to increase TGF-13 bioactivity in media of MC whose PKC had been down-regulated. Consistent with the effects of GFX shown in Figure 3 , PKC down-regulation had no effect on basal accumulation of total TGF-13. However, the basal level of the active fraction of TGF-13 in media was significantly reduced compared to that seen in media of control MC cultures. Figure 5 shows the effect of a low concentration (50 nM) of the PKC agonist phorbol dibutyrate (PDBu) on TGF-13 bioactivity in media from MC. Low concentrations (50 to 100 nM) of PDBu have been shown to rapidly (15 mm) activate PKC in MC [12] . Despite a decline in the total PKC content of MC to 50 to 60% of initial values, PKC activation in MC in response to 50 to 100 flM PDBu is sustained for at least six days, as reflected by a persistent enhancement of MARCKS protein phosphorlyation [12] . As shown in Figure 5 (Fig. 5 ). As noted above, PMA also reduced the basal levels of active but not total TGF-p. The preceding studies showed that inhibition of PKC decreased and activation of PKC increased the fraction of total TGF-f3 in the active state. In media of control MC cultures, 3.1% of the total TGF-j3 was in the active form. In MC exposed to GFX for 24 hours, this value was reduced to 1.1%. After 48 hours exposure of MC to 0.5 tM PMA, the active fraction of TGF-f3 in media was 1.5% of total activity. In MC cultured with U-46619, the fraction of total TGF-/3 in the active form was 5.6%. PDBu also increased the percentage of TGF-fJ in the active form to approximately 4% (Fig. 5) . 
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Time, hours The dose of anti-TGF-131 antibody employed in these studies was sufficient to block the 50% increase in Fn synthesis induced in MC exposed to 25 M exogenous TGF-13 for six hours. By contrast, 2 LM GFX blocked U-46619 induced increases in both TGF-j3 bioactivity and Fn synthesis at six hours and at the later time points. [17] and is dependent on TGF-f3 bioactivity [28] . selective for PKC relative to other kinases. Accordingly, the influence of down-regulation of PKC in MC was also examined to assess further the role of PKC in expression of U-46619 stimulated increases in TGF-13 bioactivity. As shown in Figure 2 and previously reported [17] , down-regulation of PKC by prior exposure of MC to PMA blocked the action of U-46619 to increase Fn synthesis. The present data demonstrate that PKC down-regulation also prevented the increases in TGF-13 bioactivity in MC culture media induced by both U-46619 and PDBu. In contrast, down-regulation of PKC failed to alter the increases in Fn synthesis induced in MC by exogenous TGF-p. These latter findings, and the failure of exogenous TGF-p to activate PKC in MC (Fig. 1) , suggest that the action of TGF-/3 on Fn synthesis in these cells is not dependent on PKC. However, since not all PKC isozymes are down-regulated by phorbol ester [38] , it is possible that PKC isoforms such as PKC-&, which is resistant to downregulation, could be involved in the expression of actions of TGF-13 on Fn synthesis.
The concentrations of both active and latent TGF-j3 found in MC culture media in the current studies are low relative to those previously reported by Kaname et a! [35] and Kagami et al [31] . With respect to the active fraction, these groups reported basal media concentrations of TGF-j3 of 14 M after 24 hours [35] and 10 M after 48 hours culture of MC [31] . The fraction of active TGF-p constituted 4% [35] and 12% [31] of total TGF-f3 bioactivity under basal MC incubation conditions, compared to 3.1% in the present study. Whether these differences are a function of the MC culture conditions, the processing of the media prior to bioassay (addition of protease inhibitors, dialysis of samples) or other factors is not certain. The concentrations of TGF-p detected in MC culture media in the present study are also much lower than the concentrations of exogenous TGF-13 often used [39] [40] [41] [42] to stimulate increases in mRNA levels for Fn (40 to 800 pM) or protein and collagen synthesis (10 to 120 pM) in MC. In the current study, increases in Fn synthesis by MC were observed in response to concentrations of TGF-p1 as low as 1 M (Fig. 1) , with maximal stimulation in response to 50 p. The responsiveness of Fn synthesis to TGF-13 in MC thus approximates that of collagenase sensitive proline incorporation which was maximally stimulated by 10 M TGF-p [42] . MacKay et al also found that high affinity binding of TGF-/3 in MC was saturated at a concentration of between 10 and 15 p, with a kD of 5 M [42] . The concentration response relationship observed between TGF-f3 and fibronectin synthesis is therefore consistent with the reported kD for TGF-p in MC. Although the basal levels of active TGF-J3 observed in the present study are below those previously reported in culture media of MC, the increases in active TGF-)3 (0.53 to 1.3 p, Fig. 3 ) induced by 24 hours of exposure to U-46619 appear sufficient to mediate the action of U-46619 on Fn synthesis, at this time, in view of the sensitivity of this parameter to a concentration of exogenous TGF-!3 as low as 1 p. The low basal levels of active TGF-j3 in the control MC which had been rendered quiescent by prior reduction in the concentration of FCS in the culture media probably did not modulate Fn synthesis in the control cells. This is implied by: (a) the failure of PKC inhibition or down-regulation to alter basal rates of Fn synthesis despite a concurrent reduction in active TGF-; and (b) the absolute concentration of active TGF-f3 in media under control conditions (0.6 M or less), which was below the minimal concentration of exogenous TGF-p (1 pM) effective in stimulating Fn synthesis.
In contrast to the inhibitory action of anti-TGF-13 antibody on increases in Fn synthesis observed in MC exposed to TX for 24 hours or longer, anti-TGF-j3 antibody failed to block the 40% increases in Fn synthesis after only six hours of culture with TX. Moreover, the small increases in the active fraction of TGF-f3 (<0.5 pM) observed after this brief exposure to U-46619 were likely inadequate to account for the corresponding early increases in Fn synthesis, since 25 M exogenous TGF-p yielded only modest increases in Fn synthesis in this time frame. In our earlier studies [17] , we demonstrated that inhibition or down-regulation of PKC activity prevented both the early (6 hr) and later increase in Fn synthesis induced by TX. In the current study, PKC inhibition with GFX similarly blocked both the early and subsequent increases in TGF-(3 induced by TX. Nevertheless, the failure of antibody to TGF-p to block the acute effects of TX on Fn synthesis suggest that this action is not dependent on TGF-13.
In this regard, serum, a potent activator of PKC [12] , rapidly increases Fn gene expression [43] . Similarly, Naham, Rovin and Leonhart [44] reported increases in Fn mRNA in MC 30 minutes after exposure to phorbol ester, with subsequent increases in both matrix and medium Fn content by four hours. These rapid responses and the acute increases in Fn synthesis induced by TX may reflect genomic effects of PKC expressed independent of TGF-j3.
A number of prior observations have implicated PKC as a signal for increased TGF-13 synthesis and/or secretion. Thus, Akhurst, Fee and Balmain reported phorbol ester induced TGF-$3 mRNA in epidermal cells [45] . Moreover, regions in the TGF-13 gene that are responsive to phorbol ester have been identified [46] . PKC has also been implicated in increases in TGF-p mRNA [33, 35] and TGF-13 bioactivity [47] observed in vascular smooth muscle cells. In MC, several activatOrs of PKC in addition to phorbol ester and U-46619 have now been shown to increase TGF-3 mRNA levels, bioactivity, or both. These include high concentrations of glucose [29] , angiotensin II [31] , and low density lipoproteins [30] , all of which also increase MC matrix protein synthesis. Ziyadeh et a! [29] found that high concentrations of glucose, which activate PKC via de novo synthesis of diacyiglycerol [48] , stimulate increased TGF-13 mRNA by murine MC. Kagami et al [31] showed that angiotensin II, another known agonist of PKC [49] , increased de novo synthesis + Active TGFI3 / Mesangial matrix expansion TGF-/3 mRNA levels in rat MC and TGF-f3 bioactivity in MC culture media. We recently found that exposure of rat MC to low density lipoproteins activated PKC and increased media TGF-/3 bioactivity [30] . Analogous to the finding with U-46619 in the present study, inhibition or down-regulation of PKC activity in MC prevented the increases in TGF-13 bioactivity induced by low density lipoproteins [30] . By contrast, our findings do not implicate PKC isoforms that are down-regulated by phorbol esters or inhibited by GFX in the pathway by which TGF-/3 stimulates Fn synthesis in MC. Thus, exogenous TGF-13 failed to activate PKC (Fig. 1) , and downregulation of PKC in MC (Fig. 2) or the PKC inhibitor GFX (data not shown) failed to alter the increases in Fn synthesis induced by exogenous TGF-/3. There are data both supporting and rejecting a role for PKC activation in the mediation of TGF-13 effects on cell function. Muldoon, Rodland and Magun [50] reported that prolonged treatment of fibroblasts with TGF-p stimulated calcium influx and phosphatidylinositol turnover, while Markovac and Goldstein [51] found that TGF-f3 caused a redistribution of PKC from the cytosolic to particulate fraction in microvessels of rat brains. More recently, Bradham et a! [52] concluded that activation of PKC was necessary for TGF-p induced downregulation of collagen II expression in chondrocytes. However, this was based on studies utilizing the serine/threonine protein kinase inhibitor H-7. Ohtsuki and Massague [531 had previously shown that H-7 inhibits responses to TGF-13 by interfering with a phosphorylation step unrelated to PKC. Results of two recent studies are consistent with our findings in MC. Anderson et a! [54] reported that TGF-/3 did not activate PKC in either LLC-PK1 or MDCK renal epithelia! cell lines, and Mu, Ware and Kent [55] found analogous results in vascular smooth muscle cells derived from human saphenous veins. Thus, TGF-j3 may activate PKC in some cells, but this action is not apparent in MC and other renal cell lines.
As noted above, increases in TGF-f3 mRNA, TGF-j3 bioactivity, or both have been found in response to activators of PKC, including phorbol ester, glucose, low density lipoproteins, and angiotensin II [29-31, 33, 35, 42, 43] . In the present study, U-46619 and phorbol ester increased latent TGF-f3 and this action was also linked to activation of PKC. In view of earlier reported changes in mRNA levels for TGF-13, the increases in latent TGF-/3 bioactivity observed in response to U-46619 and phorbol ester in MC may reflect PKC induced increases in TGF-13 synthesis, and perhaps a direct genomic action of PKC [45] . However, the conversion of TGF-/3 from the latent to the active form is thought to be a critical determinant of expression of the biologic action of TGF-13, and one that may be physiologically regulated [56] . In the present studies, only a small proportion of total TGF-f3 (3%) in MC culture media was present in the active form under control conditions. This proportion fell to even lower levels (1%) when PKC was inhibited or down-regulated, whereas basal levels of latent TGF-f3 did not change. Conversely, the active fraction rose modestly (4 to 5%) in response to U-46619 and phorbol ester, an increase that was prevented by PKC inhibition or down-regulation. There have been no studies of TGF-f3 activation by MC in culture. However, marked increases in the active relative to the latent fraction of TGF-p were observed in MC exposed to angiotensin II, consistent with an independent action of this agent on TGF-13 activation [31] . In smooth muscle and endothelial cell co-cultures, activation of TGF-p requires a close apposition of the two cell types and involves the conversion of plasminogen to the proteolytic active plasmin by plasminogen activation [56] [57] [58] . Plasmin then cleaves at the amino terminus of the propeptide and releases active TGFI3. PKC has been shown to induce tissue-type plasminogen activator (tPA) in some cells [59] . Moreover, human MC synthesize and secrete tPA [60] . Accordingly, it is possible that U-46619 stimulation of PKC may increase tPA, and thereby enhance activation of latent TGF-f3 via an increase in plasmin. In preliminary studies (unpublished observations), we have observed that aprotinin, a protease inhibitor which suppresses plasmin activity, abolished increases in the active fraction of TGF-13 induced in MC by PDBu. This is consistent with PKC mediated induction of proteolytic activity in the process of TGF-/3 activation in MC.
In conclusion, the current findings show that activation of PKC in MC by TX increases TGF-p bioactivity. The latter in turn stimulates sustained increases in Fn synthesis in MC by processes not dependent on PKC. They provide further evidence for the schema shown in Figure 7 , which summarizes our current understanding of potential mechanisms that may be common to several stimuli which enhance MC matrix protein accumulation in vitro, and may also contribute to the development of glomerulosclerosis. TX, angiotensin II, and low density lipoproteins bind to specific membrane receptors, stimulate phosphatidylinositol hydrolysis, and thereby increase cellular diacyiglycerol production and activate PKC. High glucose concentrations also increase PKC, but do so by increasing the de novo synthesis of diacylglycerol [48, 61] . Perhaps by a direct nuclear effect [45] PKC may increase the synthesis and secretion of latent TGF-j3. PKC may also be involved in the conversion of latent TGF-f3 to the biologically active form by pathways yet to be explored. Active TGF-13 then functions in an autocrine fashion to stimulate sustained matrix protein synthesis in MC, inhibit matrix degradation [18, 19] , and thereby possibly contribute to the pathogenesis of glomerulosclerosis. However, as noted above, activation of PKC by TX, and possibly other agonists, also results in a rapid increase in Fn synthesis which does not appear to involve TGF-j3. The relevance of this early PKC action to the sustained stimulation of matrix production by the MC is not certain.
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